---

• Deerfield, IL


• Contact:
  Jeff Himawan
  
• Formerly Known As: Horizon Therapeutics
• Acquisition
• Acquired by: Rival Raptor
• Exit date: September 16, 2016

Related News

• Horizon Pharma Announces Stockholder Approval of Its Acquisition of Vidara Therapeutics
• Investors Set Their Sights on Horizon Pharma
• Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma PLC
• Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO® and Provides 2014 Guidance
• Horizon Pharma Announces Third Quarter 2013 Financial Results, Reports Net Revenue of $26.2 Million
• Horizon Pharma to Receive Approval of DUEXIS (R) from the United Kingdom (UK) MHRA
• Horizon Announces FDA Approval of RAYOS Delayed-Release Tablets for Rheumatoid Arthritis
• Horizon Pharma Enters Agreement with Grunenthal for Commercialization of DUEXIS in Latin America
• Horizon Pharma and Mallinckrodt, Pharmaceuticals Business of Covidien, Enter Co-Promotion Agreement
• Annals of the Rheumatic Diseases Publishes Pivotal Phase 3 Study Demonstrating Efficacy and Safety of RAYOS(R) in Combination With DMARD Therapy in Rheumatoid Arthritis Patients
• Horizon Pharma Gears Up for Sales of First Products
• Horizon Pharma Enters into Exclusive Agreement with Mundipharma for Commercialization of LODOTRA® (modified-release prednisone) in Latin America
• Horizon Pharma Announces $50.8 Million Private Placement
• Horizon Pharma Announced this Morning the Launch of DUEXIS in the U.S.
• Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTRA (R) New Drug Application for Review for the Treatment of Rheumatoid Arthritis
• Horizon Pharma and Sanofi Announce FDA Approval of DUEXIS® Commercial Manufacturing Facility
• Horizon Pharma Receives U.S. Patent Allowance for DUEXIS in the United States
• Horizon Pharma Submits New Drug Application for LODOTRA for the Treatment of Rheumatoid Arthritis
• Horizon Shine:  A New Day Is About To Dawn with Duexis and LODOTRA
• Horizon Pharma Receives U.S. Patent Allowance for DUEXIS (ibuprofen/famotidine)
• Horizon Pharma Announces Pricing of Its Initial Public Offering
• Venture Firms Offer to Invest in Revamped Horizon Pharma IPO
• Horizon Pharma Announces FDA Approval of DUEXIS (ibuprofen/famotidine) for the Relief of the Signs and Symptoms of Rheumatoid Arthritis and Osteoarthritis
• Horizon Pharma Takes $35M Bridge Loan to Reach IPO Day
• Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints